

Agustin Casimiro-Garcia

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2211704/publications.pdf>

Version: 2024-02-01

16
papers

623
citations

687363

13
h-index

940533

16
g-index

17
all docs

17
docs citations

17
times ranked

801
citing authors

#	ARTICLE	IF	CITATIONS
1	Discovery of a JAK3-Selective Inhibitor: Functional Differentiation of JAK3-Selective Inhibition over pan-JAK or JAK1-Selective Inhibition. <i>ACS Chemical Biology</i> , 2016, 11, 3442-3451.	3.4	127
2	Design of a Janus Kinase 3 (JAK3) Specific Inhibitor 1-((2 <i>S</i> ,5 <i>R</i>)-5-((7 <i>H</i> -Pyrrolo[2,3- <i>d</i>]pyrimidin-4-yl)amino)-2-methylpiperidin-1-yl)prop-2-en-1-one (PF-06651600) Allowing for the Interrogation of JAK3 Signaling in Humans. <i>Journal of Medicinal Chemistry</i> , 2017, 60, 1971-1993.	6.4	111
3	Identification of Cyanamide-Based Janus Kinase 3 (JAK3) Covalent Inhibitors. <i>Journal of Medicinal Chemistry</i> , 2018, 61, 10665-10699.	6.4	55
4	Discovery of a Series of Imidazo[4,5- <i>b</i>]pyridines with Dual Activity at Angiotensin II Type 1 Receptor and Peroxisome Proliferator-Activated Receptor- β . <i>Journal of Medicinal Chemistry</i> , 2011, 54, 4219-4233.	6.4	51
5	ATP-Mediated Kinome Selectivity: The Missing Link in Understanding the Contribution of Individual JAK Kinase Isoforms to Cellular Signaling. <i>ACS Chemical Biology</i> , 2014, 9, 1552-1558.	3.4	51
6	The Discovery of (2 <i>R</i> ,4 <i>R</i>)- ϵ -(4-chlorophenyl)- ϵ -N-(2-fluoro-4-(2-oxopyridin-1(2 <i>H</i>)- α yl)phenyl)- ϵ -methoxyproline-2,2-dicarboxamide (PD 0348292), an Orally Efficacious Factor Xa Inhibitor. <i>Chemical Biology and Drug Design</i> , 2007, 70, 100-112.	3.4	38
7	Effects of modifications of the linker in a series of phenylpropanoic acid derivatives: Synthesis, evaluation as PPAR β/δ dual agonists, and X-ray crystallographic studies. <i>Bioorganic and Medicinal Chemistry</i> , 2008, 16, 4883-4907.	3.0	30
8	PF-07059013: A Noncovalent Modulator of Hemoglobin for Treatment of Sickle Cell Disease. <i>Journal of Medicinal Chemistry</i> , 2021, 64, 326-342.	6.4	29
9	Progress in the discovery of Factor Xa inhibitors. <i>Expert Opinion on Therapeutic Patents</i> , 2006, 16, 119-145.	5.0	26
10	Design, synthesis, and evaluation of imidazo[4,5- <i>c</i>]pyridin-4-one derivatives with dual activity at angiotensin II type 1 receptor and peroxisome proliferator-activated receptor- β . <i>Bioorganic and Medicinal Chemistry Letters</i> , 2013, 23, 767-772.	2.2	25
11	Synthesis and evaluation of novel β -heteroaryl-phenylpropanoic acid derivatives as PPAR β/δ dual agonists. <i>Bioorganic and Medicinal Chemistry</i> , 2009, 17, 7113-7125.	3.0	21
12	Exploration of 4,4-disubstituted pyrrolidine-1,2-dicarboxamides as potent, orally active Factor Xa inhibitors with extended duration of action. <i>Bioorganic and Medicinal Chemistry</i> , 2009, 17, 2501-2511.	3.0	16
13	Structure-based Drug Design of Pyrrolidine-1, 2-dicarboxamides as a Novel Series of Orally Bioavailable Factor Xa Inhibitors. <i>Chemical Biology and Drug Design</i> , 2007, 69, 444-450.	3.2	15
14	Selective, Small-Molecule Co-Factor Binding Site Inhibition of a Su(var)3 ϵ 9, Enhancer of Zeste, Trithorax Domain Containing Lysine Methyltransferase. <i>Journal of Medicinal Chemistry</i> , 2019, 62, 7669-7683.	6.4	14
15	Investigation of the asymmetric Birch reduction α -alkylation of a chiral 5-arylbenzamide containing a carbamate group. <i>Tetrahedron Letters</i> , 2006, 47, 2739-2742.	1.4	8
16	Discovery of a Series of Pyrimidine Carboxamides as Inhibitors of Vanin-1. <i>Journal of Medicinal Chemistry</i> , 2022, 65, 757-784.	6.4	6